News roundup [abridged versions appear in the paper journal]

NICE issues guidance on diabetes treatments

BMJ 2003; 327 doi: 10.1136/bmj.327.7414.520-d (Published 4 September 2003)
Cite this as: BMJ 2003;327:520.5

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Andrew Iles
  1. BMJ

    The use of thiazolidinediones (glitazones) for type 2 diabetes is to be restricted, after the release of new guidelines by the National Institute for Clinical Excellence (NICE).

    NICE recommends that the treatment should be offered only to patients who cannot tolerate the combination treatment of metformin and a sulphonylurea. It no longer recommends glitazones to reduce blood glucose concentrations when treatment with metformin and a sulphonylurea has failed.

    Glitazones directly target insulin resistance and preserve the (cells in the pancreas. Currently doctors in the United Kingdom prescribe glitazones in addition to combination treatment, …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular